Relationship between pulmonary function and peripheral vascular function in older Chinese: Guangzhou biobank cohort study-CVD by Pan, Jing et al.
 
 
University of Birmingham
Relationship between pulmonary function and
peripheral vascular function in older Chinese:
Guangzhou biobank cohort study-CVD
Pan, Jing; Xu, Lin; Lam, Tai Hing; Jiang, Chao Qiang; Zhang, Wei Sen; Zhu, Xiao-Feng; Jin,
Ya Li; Thomas, G Neil; Cheng, Kar; Adab, Peymane
DOI:
10.1186/s12890-018-0649-x
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Pan, J, Xu, L, Lam, TH, Jiang, CQ, Zhang, WS, Zhu, X-F, Jin, YL, Thomas, GN, Cheng, K & Adab, P 2018,
'Relationship between pulmonary function and peripheral vascular function in older Chinese: Guangzhou
biobank cohort study-CVD', BMC Pulmonary Medicine, vol. 18, no. 74. https://doi.org/10.1186/s12890-018-0649-
x
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 22/05/2018
https://doi.org/10.1186/s12890-018-0649-x
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
RESEARCH ARTICLE Open Access
Relationship between pulmonary function
and peripheral vascular function in older
Chinese: Guangzhou biobank cohort
study-CVD
Jing Pan1 , Lin Xu2,3, Tai Hing Lam1,3*, Chao Qiang Jiang1*, Wei Sen Zhang1, Feng Zhu1, Ya Li Jin1,
G. Neil Thomas4, Kar Keung Cheng4 and Peymane Adab4
Abstract
Background: Findings describing the relationship between pulmonary function and peripheral vascular function
have been inconclusive. We explored this relationship in Guangzhou Biobank Cohort Study-Cardiovascular
Subcohort (GBCS-CVD).
Methods: Brachial-ankle pulse wave velocity (baPWV) and ankle brachial index (ABI) were measured by a waveform
analyser, and pulmonary function by turbine flowmeter spirometry. Predicted forced expiratory volume in 1 s (FEV1)
and forced vital capacity (FVC) were derived using equations for Chinese. Regression analyses were used to investigate
the association.
Results: Of 1528 older Chinese, 980 (64.1%) had arterial stiffness (baPWV ≥1400 cm/s), but only 29 (1.9%) had
peripheral arterial disease (PAD) (ABI < 0.9). The mean (±standard deviation, SD) baPWV was 1547 (±298) cm/s
and mean (±SD) ABI 1.09 (±0.09). Before and after adjusting for potential confounders, baPWV was negatively
associated with FEV1 and FVC % predicted (% predicted = observed/predicted × 100%) (adjusted β: − 0.95 and
− 1.16 respectively, p < 0.05), and ABI was marginally non-significantly positively associated with FEV1% predicted
(adjusted β 0.02, p = 0.32) and FVC% predicted (adjusted β 0.02, p = 0.18). Compared to participants in the highest
tertile of pulmonary function, those in the lowest had higher risk of arterial stiffness (adjusted odds ratio (AOR) 1.
51, 95% CI 1.09–2.10 for FEV1 and AOR 1.69, 95% CI 1.22–2.33 for FVC), but the higher risk of PAD was marginally
non-significant (AOR 1.64, p = 0.42 for FEV1 and AOR 1.65, p = 0.24 for FVC).
Conclusion: In older relatively healthy normal weight Chinese, pulmonary function was inversely dose-dependently
associated with arterial stiffness, while the association with PAD was much weaker.
Keywords: Pulmonary function, Arterial stiffness, Peripheral arterial disease (PAD), Vascular function
Background
Cardiovascular disease (CVD), a leading cause of disabil-
ity and mortality worldwide, has been increasing rapidly
in China [1]. Poorer pulmonary function has been re-
ported to be a risk factor for CVD mortality in general
population [2], but the mechanisms are unclear. A pos-
sible mechanism may be through increasing arterial stiff-
ness, as indicated by elevated pulse wave velocity (PWV)
or vascular plaque formation, as indicated by reduced
ankle brachial index (ABI). The prevalence of peripheral
arterial disease (PAD) (ABI < 0.9) was higher in patients
with chronic obstructive pulmonary disease (COPD)
(n = 2088) than in age- and sex-matched control subjects
without COPD (n = 4420) (8.8% vs. 1.8%) in the German
COPD and Systemic Consequences-Comorbidities Net-
work (COSYCONET) study [3]. Previous studies describ-
ing the association between pulmonary function and
vascular dysfunction were inconclusive. Many [4–10], but
not all [11, 12], of the studies showed that reduced
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pulmonary function was associated with a higher risk
of vascular dysfunction. The discrepancy could be due
to interaction, diffrences in study design and, study
population (patients or relatively healthy subjects),
sample size, and variation in confounding factors con-
sidered [5, 7, 8, 10–16].
Peripheral vascular dysfunction has been reported
to be influenced by many factors including adiposity
[17], blood pressure [18], age [18], physical activity
[19] and inflammatory biomarkers such as C-reactive
protein [20], which are also associated with pulmon-
ary function. Thus the association between vascular
dysfunction and pulmonary function could be influ-
enced by, or depend on these factors. Most of the
studies adjusted for age, sex and body mass index
(BMI) [4–6, 8, 10–14], but did not adjust for blood
pressure, smoking status, physical activity, inflamma-
tory biomarkers and lipids [4, 9, 10]. Although the
association did not attenuate substantially after con-
founder adjustment in most studies, two reported no
association after adjusting for sex, age, BMI, total
cholesterol/high-density lipoprotein-cholesterol ratio,
hypertension, diabetes, drinking and smoking in 678
adult Japanese Americans [11], and after adjusting for
sex, age, smoking, highly sensitive C-reactive protein,
glucose concentrations, cholesterol-high-density lipo-
protein ratio, pulse oximetry oxygen saturation and
emphysema severity in 177 patients with chronic ob-
structive pulmonary disease (COPD) [12]. Only three
studies examined whether the association varied by
smoking status [4, 21] or sex [14, 21].
Moreover, most of these studies were from Western
populations. We found only three studies on the rela-
tionship between pulmonary function and vascular func-
tion in Asian populations [4, 5, 22] and of them, one
was a small hospital-based study (n = 155) in China
showing a negative association between baPWV and
forced expiratory volume in 1 s (FEV1) and FEV1/forced
vital capacity (FVC) ratio after adjusting for age, sex,
BMI and smoking status [5]. The other 2 studies were in
Japanese populations: a clinical study with only 45
hypertensive patients showing cardio-ankle vascular
index (CAVI) was negatively associated with lung
function [22], and the other a population-based study
(n = 8790) which showed a negative association between
airflow limitation and baPWV only in smokers [4]. We
studied the association between pulmonary function and
peripheral vascular function in older Chinese in the
Guangzhou Biobank Cohort Study-CVD Sub-study.
Methods
Subjects
The Guangzhou Biobank Cohort Study (GBCS), a
three-way collaboration among the Guangzhou Number
12 Hospital, the Universities of Hong Kong and Birming-
ham, recruited 30,518 older Chinese in Guangzhou at
baseline from 2003 to 2008 [23]. The Cardiovascular
Disease Sub-cohort (GBCS-CVD) included 1996 par-
ticipants from phase 3 and details have been reported
elsewhere [24]. Trained interviewers collected infor-
mation on the demographic characteristics, family and
personal disease and medication history and lifestyle,
including smoking, alcohol drinking and physical ac-
tivity according to the International Physical Activity
Questionnaire (IPAQ) using a standardized computer-based
questionnaire. Physical examination included height,
weight, waist circumference and blood pressure.
Blood glucose, lipids and high-sensitivity C-reactive
protein (hs-CRP) were assayed after an overnight
(> 8 h) fast. Hypertension was defined as systolic
blood pressure (SBP) ≥140 mmHg, diastolic blood
pressure (DBP) ≥90 mmHg, or self-reported use of
antihypertensive medication. Diabetes mellitus (DM)
was defined as fasting glucose ≥7.0 mmol/L and/or
self-reported DM. Asthma was based on self report
of whether a doctor had ever diagnosed them with
asthma. Ethical approval was granted by the Guangzhou
Medical Ethics Committee of the Chinese Medical
Association. All participants gave written, informed
consent before participating.
Exposure indicators
Spirometry was done by a turbine flowmeter (Cosmed
microQuark, Rome, Italy), and details of the methods
and results on other research questions have been re-
ported elsewhere [25, 26]. Briefly, the pulmonary
function test was conducted in a standing position
following standard procedures, with at least three ma-
neuvers, and the best measure of FEV1 and FVC were
recorded. Predicted values for FEV1 and FVC were
derived using the equations of Ip and colleagues for
Chinese [27]. The cutoff points of the tertiles of the
FEV1% predicted (% predicted = observed/predicted ×
100%) were as follows: tertile 1, > 103.4%; tertile
2, 90.5–103.4%; and tertile 3 < 90.5%. The cutoff
points of the tertiles of FVC% predicted were as
follows: tertile 1 > 102.2%; tertile 2, 89.9–102.2%; and
tertile 3, < 89.9%. These cutoff points have been used
in our previous paper [26]. We defined COPD based
on the presence of airflow obstruction, using the
GOLD definition of FEV1/FVC < 0.70. Restrictive
pattern of lung disease was defined as FEV1/FVC
≥0.70, FVC% predicted < 0.80.
Study outcomes
Details of the methods for measuring baPWV and ABI
with other results have been reported [24, 28, 29].
Briefly, they were measured in the supine position after
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5 min of rest using an automatic waveform analyser
(BP-203RPE; Colin Medical Technology, Komaki,
Japan), an automated recording device that calculated
the time delay between 2 pulse waves recorded simul-
taneously [24]. Data of the waveforms of both ankles
and brachia were stored, the time interval between
the wave front of the brachial waveforms and the
waveforms of the ankles was automatically measured,
which was defined as ΔT. The distance of each seg-
ment (La − Lb) was automatically calculated based on
the patient’s height. Afterward, baPWV was calculated
using the following equation: baPWV (in centimetres
per second) = (La − Lb)/ΔT. The mean of the left and
right baPWV (average baPWV) was obtained from all
subjects and used in the analysis, and the max of the
left and right baPWV was also used for sensitivity
analysis. Ankle SBP and brachial SBP were measured
and ABI was calculated using the equation: ABI =
ankle SBP/brachial SBP. The lowest value of the left
and right ABI was used for analysis. Higher baPWV
(indicating greater arterial stiffness) was defined as
baPWV ≥1400 cm/s [30], and lower ABI (indicating
peripheral arterial disease (PAD)) as ABI < 0.9 [31].
Statistical analysis
All data analysis was performed using Stata/SE V.12.0
(StataCorp LP, 4905 Lakeway Drive, College Station,
TX77845 USA). Continuous variables were analysed
using independent sample t-test and categorical vari-
ables using χ2 test. Multivariable linear regression was
used to calculate regression coefficient (β) and 95%
confidence interval (CI) of pulmonary function indica-
tors with vascular function. Multivariable logistic re-
gression was used to calculate odds ratio (OR) of
presence of arterial stiffness, and presence of PAD for
(a) FEV1% predicted tertiles, and (b) FVC% predicted
tertiles with and without adjustment for following
potential confounders: age (years), sex, waist circum-
ference (cm), education (primary or below, middle
school, college or above), smoking (never, former,
current smokers (0–29 pack-years) and current smokers
(> 30 pack-years)), IPAQ physical activity (physically ac-
tive, moderate and inactive), diastolic blood pressure
(mmHg), triglycerides, fasting plasma glucose (mmol/l),
COPD, asthma and medications (aspirin and/or lipid low-
ering medication).
We tested for interaction between pulmonary func-
tion indicators and sex, and smoking status. As we
found no evidence that the association of pulmonary
function with vascular dysfunction (arterial stiffness
or PAD) varied by sex (P values for interaction: 0.19–
0.99) or smoking status (P values for interaction:
0.15–0.69), we conducted all analysis pooling men
and women together with adjustment for sex and
smoking. We also performed sensitivity analysis exam-
ining the association of pulmonary function indicators
with vascular dysfunction by sex and by smoking sta-
tus. All significance tests were 2-tailed, with p < 0.05
as statistically significant.
Results
Of 1996 participants in GBCS-CVD, 1528 (76.6%)
participants with valid data were included in this
analysis. Their mean age was 59.3 years (standard
deviation, 6.9). Half of the participants were women
(50.7%), 64.1% had arterial stiffness, and 1.9% had
PAD. 133 (9.2%) participants had obstructive COPD
and 154 (10.1%) had restrictive respiratory pattern.
Table 1 shows that compared with participants with-
out COPD, those with COPD were older, had lower
education and more smokers. They also had lower
BMI, cholesterol and pulmonary function, higher
blood pressure and baPWV, and higher prevalence of
arterial stiffness and PAD, but the differences of his-
tory of asthma (based on reporting a doctor diagno-
sis of the condition), hypertension and diabetes,
medication, physical activity level and ABI were
non-significant.
Table 2 shows that baPWV was significantly inversely
associated with all pulmonary function indicators (Crude
β ranged from − 3.02 to − 5.87, p < 0.001) in simple lin-
ear regression models. After adjusting for age, sex, edu-
cation, smoking, physical activity, waist circumference,
diastolic blood pressure, triglycerides, fasting plasma
glucose, COPD, asthma and medications (aspirin and/or
lipid lowering medication), the inverse association of
baPWV with FEV1% predicted (adjusted β-0.95, 95% CI
-1.70 to − 0.20) and FVC % predicted (adjusted β-1.16,
95% CI -1.98 to − 0.35) remained significant, and that of
FEV1 /FVC ratio became non-significant (p = 0.91). For
ABI, significantly positive association was found for
FEV1% predicted (β = 0.03, p = 0.045) but not FVC% pre-
dicted (β = 0.03, p = 0.06) and FEV1/FVC ratio (β = 0.02,
p = 0.54). After similar adjustment, those associations
became non-significant (adjusted β 0.02, 0.02 and −
0.005, all p values > 0.05).
Compared with participants in the highest tertile,
those in the lowest tertile of pulmonary function
showed a higher risk of arterial stiffness (adjusted odd
ratio (AOR) 1.51, 95% CI 1.09–2.10 for FEV1% pre-
dicted and AOR 1.69, 95% CI 1.22–2.33 for FVC%
predicted) (Table 3 and Table 4). The AOR of lowest
tertile of pulmonary function with higher risk of
lower ABI was statistically non-significant (AOR 1.64,
95% CI 0.54–5.01 for FEV1% predicted and AOR 1.65,
95% CI 0.63–4.29 for FVC% predicted). Poorer pul-
monary function showed dose-response relationship
with arterial stiffness (P values for trend < 0.03),
Pan et al. BMC Pulmonary Medicine  (2018) 18:74 Page 3 of 10
instead of PAD (P values for trend > 0.05). Stratified
analysis by sex (Appendix 1 Table 5 and (Appendix 2
Table 6) and by smoking status (Appendix 3 Table 7 and
Appendix 4 Table 8) showed similar tendencies. Sensi-
tivity analysis of the relationship between pulmonary
function and the maximal values of left and right
baPWV showed similar results with the means of left
and right baPWV (data not shown).
Discussion
Our study was the first population-based study on older rela-
tively healthy and normal weight Chinese with comprehensive
adjustment for many potential confounders showing that pul-
monary function was inversely dose-dependently associated
with arterial stiffness, while the association with PAD was
much weaker. Furthermore, we found no evidence
that the association varied by sex or smoking status.
Our study suggests reduced pulmonary function might in-
crease risk of cardiovascular disease through actions on ar-
terial stiffness in general population. Several hospital-based
studies showed an inverse association between arterial stiff-
ness and pulmonary function [5, 6, 12, 13, 22] despite small
sample size (n < 250). The COSYCONET study found that
8.8% of patients with COPD had PAD, compared to only
1.8% in age- and sex-matched control subjects without
COPD [3]. Our findings are consistent with a few earlier
population-based studies, including the Atherosclerosis Risk
in Communities (ARIC) Study (n= 14,000) [21], the
Nagahama Study (n = 8790) [4], the Whitehall II Study
(n = 5392) [8], the Copenhagen City Heart Study (n= 3374)
[7], the Caerphilly Prospective Study (n = 827) [9], the “Men
born in 1914” cohort (n = 207) [32] and the Burden of Lung
Disease (BOLD) study (n = 108) [10], which were pre-
dominantly conducted in Caucasian populations. PWV
[4, 8–10], ABI [21, 32] and aortic augmentation index
(AIx) [14] were used as indicators for vascular func-
tion in these studies. ABI indicates PAD, while PWV
indicates arterial stiffness. The combination of both
should provide more comprehensive information of
Table 1 Characteristics of the study sample
All Non-COPD COPD P value
Number 1528 1395 133
Age, y 59.3 ± 6.9 58.8 ± 6.6 64.7 ± 7.4 < 0.001
Education, n (%)
≤ Primary 420 (27.5) 361 (25.9) 59 (44.4) < 0.001
Middle school 913 (59.7) 855 (61.3) 58 (43.6)
≥ College 195 (12.8) 179 (12.8) 16 (12.0)
Smoking, n (%)
Never 1033 (67.6) 998 (70.8) 45 (33.8) < 0.001
Former 230 (15.1) 198 (14.2) 32 (24.1)
Current (0–29
pack-years)
127 (8.3) 107 (7.67) 20 (15.0)
Current (≥ 30
pack-years)
138 (9.0) 102 (7.3) 36 (27.1)
IPAQ Physical activity, n (%)
High 917 (60.1) 845 (60.6) 72 (54.2) 0.18
Moderate 456 (29.8) 407 (29.2) 49 (36.8)
Low 155 (10.1) 143 (10.3) 12 (9.0)
Body mass index, kg/m2 23.8 ± 3.1 23.9 ± 3.0 22.7 ± 3.0 < 0.001
Waist circumference, cm 78.5 ± 9.0 78.5 ± 9.0 78.8 ± 8.5 0.76
History of diseases
Asthma, n (%) 19 (1.2) 19 (1.4) 0 (0.0) 0.18
Hypertension, n (%) 526 (34.4) 471 (33.8) 55 (41.4) 0.08
Diabetes, n (%) 95 (6.2) 84 (6.0) 11 (8.3) 0.31
Systolic blood
pressure, mmHg
127 ± 21 127 ± 20 133 ± 23 0.003
Diastolic blood
pressure, mmHg
74 ± 11 74 ± 11 75 ± 11 0.16
Total cholesterol, mmol/l 5.82 ± 1.09 5.84 ± 1.09 5.59 ± 1.09 0.01
HDL-cholesterol, mmol/l 1.58 ± 0.40 1.58 ± 0.41 1.59 ± 0.37 0.92
LDL-cholesterol, mmol/l 3.36 ± 0.68 3.38 ± 0.68 3.22 ± 0.67 0.01
Triglycerides, mmol/l 1.83 ± 1.42 1.85 ± 1.46 1.58 ± 0.95 0.04
Fasting plasma glucose,
mmol/l
5.59 ± 1.46 5.60 ± 1.51 5.51 ± 0.93 0.48
hs-CRP, mg/l (n = 1518) 2.51 ± 2.89 2.45 ± 2.80 3.13 ± 3.66 0.009
hs-CRP, mg/la 1.45 (1.37–
1.53)
1.44 (1.34–
1.55)
1.46 (1.35–
1.58)
0.71
Aspirin, n (%) 66 (4.3) 61 (4.4) 5 (3.8) 0.74
Lipid lowering
medication, n (%)
48 (3.1) 45 (3.2) 3 (2.3) 0.54
FEV1% predicted, % 96.1 ± 16.6 98.0 ± 14.8 75.7 ± 20.6 < 0.001
FVC% predicted, % 95.9 ± 14.7 96.5 ± 13.9 89.9 ± 20.3 < 0.001
FEV1/FVC ratio, % 78.4 ± 6.9 79.8 ± 5.0 63.8 ± 7.2 < 0.001
Mean baPWV, cm/s 1547 ± 298 1535 ± 294 1664 ± 323 < 0.001
Arterial stiffness, n (%) 980 (64.1) 879 (63.0) 101 (75.9) 0.003
ABI 1.09 ± 0.09 1.09 ± 0.09 1.08 ± 0.09 0.34
Table 1 Characteristics of the study sample (Continued)
All Non-COPD COPD P value
PAD, n (%) 29 (1.9) 23 (1.7) 6 (4.5) 0.02
Results shown as mean ± standard deviation or number (%)
aResults shown as geometric mean and 95% confidence interval
IPAQ International Physical Activity Questionnaire, COPD chronic obstructive
pulmonary disease, HDL high density lipoprotein, LDL low density
lipoprotein, hs-CRP high-sensitivity C-reactive protein, FEV1 forced expiratory
volume in 1 s, FVC forced vital capacity, baPWV brachial-ankle pulse wave
velocity, ABI
ankle-brachial index, PAD peripheral arterial disease;
COPD: FEV1/FVC < 0.70
Asthma: self-reported doctor-diagnosed asthma
Hypertension: systolic blood pressure (SBP) ≥140 mmHg, diastolic blood
pressure ≥ 90 mmHg, or self-reported use of antihypertensive medication
Diabetes: fasting glucose ≥7.0 mmol/L and/or self-reported DM
Arterial stiffness: baPWV≥1400 cm/s
PAD: ABI < 0.9
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peripheral vascular function, but none of the former
studies explored both indices. Hence our study is the
first showing that poorer pulmonary function was as-
sociated with arterial stiffness, while the association
with PAD was much weaker. Our findings are in line
with our former research based on the same partici-
pants: pulmonary function was significantly associated
with common carotid artery intima-media thickness (IMT),
but the association between pulmonary function and carotid
plaque was marginally non-significant [26].
The association may result from common risk factors,
confounders, or mediators such as age, BMI, physical activ-
ity, smoking, hyperglycemia, dyslipidemia and inflammation
[4, 8, 11]. Some, such as age, sex, and BMI were adjusted for
in most studies [4–6, 8, 10–14], whereas others such as
blood pressure, smoking status, physical activity, inflamma-
tion and lipids were not, probably because of the lack of
data [4, 9, 10]. Most of the studies found that the association
could not be explained by the confounding factors [5, 8].
However, in two studies [11, 12], after adjusting for
potential confounders, no difference in vascular dysfunction
was found with pulmonary function, possibly due to the
additional adjustment for blood pressure not performed by
other studies, and the relatively small sample size (533 sub-
jects with normal and 145 with abnormal PWV) [11].
Only a few studies conducted subgroup analysis by sex
[14] or smoking status [4]. The Copenhagen City Heart
Study showed that the association between AIx and FEV1
was significant in both men and women [14], which was
in concordance with two other studies involving men only
[7, 9]. Elevated cardiovascular morbidity after menopause
in women might be due to the decreased secretion of es-
trogen which can protect cardiovascular system [33]. The
risks of vascular disease were similar in both sexes in elder
populations [34], so were the risks of vascular dysfunction
in both sexes in our older Chinese cohort. This might be
the explanation for the absence of sex interaction. Smok-
ing was reported as an important risk factor for both vas-
cular disease and poorer pulmonary function. In the
Nagahama Study, airflow limitation was associated with
Table 2 Association (regression coefficient β, 95% confidence interval) of pulmonary function with baPWV and ABI in all participants
Unadjusted β
(95% CI)
P Adjusted β
(95% CI)
P
baPWV (dependent variable)
FEV1% predicted −3.02 (−3.91 to −2.13) < 0.001 −0.95 (−1.70 to −0.20) 0.01
FVC% predicted −4.34 (−5.34 to −3.35) < 0.001 −1.16 (−1.98 to − 0.35) 0.005
FEV1 /FVC ratio −5.87 (−8.02 to − 3.71) < 0.001 0.53 (− 1.27 to 2.33) 0.91
ABI (dependent variable)
FEV1% predicted 0.03 (0.001 to 0.05) 0.045 0.02 (−0.01 to 0.04) 0.32
FVC% predicted 0.03 (−0.002 to 0.06) 0.06 0.02 (−0.01 to 0.05) 0.18
FEV1 /FVC ratio 0.02 (−0.04 to 0.08) 0.54 −0.005 (− 0.10 to 0.09) 0.92
baPWV brachial-ankle pulse wave velocity (greater variables indicate greater stiffness), ABI ankle-brachial index (lower variables indicate greater stiffness),
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
Adjusted for age, sex, education, smoking, physical activity, waist circumference, diastolic blood pressure, triglycerides, fasting plasma glucose, chronic obstructive
pulmonary disease, asthma and medications (aspirin and/or lipid lowering medication)
Table 3 Adjusted odds ratios (ORs) for the presence of peripheral vascular dysfunction by tertiles of FEV1% predicted
FEV1% predicted (%) P for trend
Tertile 1 Tertile 2 Tertile 3
Range, % > 103.4 90.5–103.4 < 90.5
Number of participants 509 509 510
Presence of arterial stiffness, n (%) 293 (57.6) 313 (61.5) 374 (73.3) < 0.001
Crude OR (95% CI) 1.00 1.18 (0.92–1.51) 2.03 (1.56–2.64)** < 0.001
Adjusted OR (95% CI) 1.00 1.14 (0.85–1.54) 1.51 (1.09–2.10)* 0.02
Presence of PAD, n (%) 5 (1.0) 10 (2.0) 14 (2.8)
Crude OR (95% CI) 1.00 2.02 (0.69–5.95) 2.85 (1.02–7.96)* 0.04
Adjusted OR (95% CI) 1.00 1.67 (0.56–4.99) 1.64 (0.54–5.01) 0.42
FEV1 forced expiratory volume in 1 s, PAD peripheral arterial disease
Adjusted for age, sex, education, smoking, physical activity, waist circumference, diastolic blood pressure, triglycerides, fasting plasma glucose, chronic obstructive
pulmonary disease, asthma and medications (aspirin and/or lipid lowering medication)
Arterial stiffness: brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s
PAD: ankle-brachial index (ABI) < 0.9
*P < 0.05; **:P < 0.01
Pan et al. BMC Pulmonary Medicine  (2018) 18:74 Page 5 of 10
baPWV in smokers, but not in non-smokers [4]. But in a
relative healthy population, there might be some under-
lying mechanisms (aging [35, 36], parallel physiological
pathways for elastic changes [37] and inflammatory re-
sponses [37]) which could have stronger impacts for the
association between lower pulmonary function and per-
ipheral vascular dysfunction than smoking. In summary,
our results are consistent with the results elsewhere and
can add to the literature by showing that poor pulmonary
function is independently associated with a higher risk of
peripheral vascular dysfunction regardless of sex and
smoking in an older Chinese population.
The underlying mechanisms for the findings are not fully
understood. There are some possible explanations. Aging is
known to influence both vascular (due to the aging-related
influence on the nonliving elastic fibers of the arterial wall)
[35] and pulmonary function (due to the aging-related de-
crease in the static elastic recoil of the lung and compliance
of the chest wall, and in the strength of respiratory muscles)
[36]. However, the present study found independent associ-
ations after adjusting for multiple confounders including
age. These findings indicate that other mechanisms instead
of aging contributed to the associations. Parallel physio-
logical pathways for elastic changes in the vasculature and
lung parenchyma tissue might be the link of the parallel
declines in arterial elasticity and lung function [12, 37, 38].
Matrix metalloprotease (MMP)-9 and tissue inhibitor of
metalloproteinase-1 (TIMP-1) which were reported to be
associated with arterial stiffness [39] were higher in patients
with emphysema [40] and COPD [41]. Alteration in elas-
tase or MMP due to genetic or proteolytic process might
influence both the connective tissue of the alveoli and arter-
ial wall, and reduce their elasticity [37]. Previous studies
have shown that arterial stiffness is associated with severity
of emphysema, independently of airflow obstruction
[12, 38]. This is hypothesised to be due to a common
pathophysiological process, with elastin degradation affect-
ing both alveolar and arterial walls [42]. In our cohort, al-
though we were not able to assess emphysema using
imaging or other measures, the participants with COPD
were almost all lean, consistent with an emphysematous or
“pink puffer” phenotype. Another mechanism might be in-
flammatory responses, which play important roles in both
vascular and respiratory system [37]. However, the BOLD
study analysed the association of pulmonary function with
arterial stiffness and inflammatory biomarkers including
C-reactive protein, interleukin 8, tumour necrosis factor
alpha, MMP-9, and tissue inhibitor of metalloproteinase 1,
but found no significant association even before adjust-
ments of age, sex, height, ethnicity, BMI, smoking status
and pack-years [10], suggesting inflammation could not
fully explain the results.
There were several limitations in our study. First, because
of the cross-sectional design, whether the associations be-
tween pulmonary function and peripheral vascular dysfunc-
tion are causal could not be ascertained. Second, we did
not perform post-bronchodilator spirometry, although all
earlier population-based studies were also based on
pre-bronchodilator measurements only. In addition, we re-
lied on airway obstruction to define COPD, with no de-
tailed measurements (e.g. CT scan, body plethysmography
and diffusion capacity of the lung for carbon monoxide) to
differentiate phenotypes. We were therefore not able to
examine whether any association differed by phenotype.
However, if such measurements would reveal more lung
abnormalities in subjects with better pulmonary function,
the strength of our observed association between pulmon-
ary function and peripheral vascular function could have
been under-estimated. Fourth, some of the confounders
could also be mediators, such as BMI and physical activity,
and the multivariate adjustment could have led to an
underestimation of the true effect size. However, it is
Table 4 Adjusted odds ratios (ORs) for the presence of peripheral vascular dysfunction by tertiles of FVC% predicted
FVC% predicted (%) P for trend
Tertile 1 Tertile 2 Tertile 3
Range, % > 102.2 89.9–102.2 < 89.9
Number of participants 509 509 510
Presence of arterial stiffness, n (%) 283 (55.6) 312 (61.3) 385 (75.5) < 0.001
Crude OR (95% CI) 1.00 1.26 (0.99–1.62) 2.46 (1.88–3.21)** < 0.001
Adjusted OR (95% CI) 1.00 1.10 (0.82–1.49) 1.69 (1.22–2.33)** 0.002
Presence of PAD, n (%) 7 (1.4) 6 (1.2) 16 (3.1)
Crude OR (95% CI) 1.00 0.86 (0.29–2.56) 2.32 (0.95–5.69) 0.04
Adjusted OR (95% CI) 1.00 0.79 (0.26–2.42) 1.65 (0.63–4.29) 0.24
FVC forced vital capacity, PAD peripheral arterial disease
Adjusted for age, sex, education, smoking, physical activity, waist circumference, diastolic blood pressure, triglycerides, fasting plasma glucose, chronic obstructive
pulmonary disease, asthma and medications (aspirin and/or lipid lowering medication)
Arterial stiffness: brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s
PAD: ankle-brachial index (ABI) < 0.9
**:P < 0.01
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impossible to completely distinguish mediating and con-
founding effects in our analysis. Finally, our sample size
might not be sufficient to detect small interaction effects.
Conclusions
Pulmonary function was inversely dose-dependently associ-
ated with arterial stiffness in older relatively healthy and
normal weight Chinese individuals after adjusting for mul-
tiple potential confounders, while the association with PAD
was much weaker. Furthermore, the association did not
vary by sex and smoking. This paper might provide more
information in the field of cardiovascular-pulmonary inter-
actions. Further intervention studies examining the effect
of improving pulmonary function on improving vas-
cular function are warranted. Non-invasive measure-
ments of vascular dysfunction in individuals with
poor pulmonary function or vice versa might help to
identify those with both conditions and who need
special clinical management.
Appendix 1
Table 5 Adjusted odds ratios (ORs) for the presence of peripheral
vascular dysfunction by tertiles of FEV1% predicted and by sex
FEV1% predicted (%) P for
trend
Tertile 1 Tertile 2 Tertile 3
Men
Range, % > 101.5 87.0–101.5 < 87.0
Number of participants 251 251 251
Presence of arterial
stiffness, n (%)
174 (69.3) 181 (72.1) 202 (80.5)
Crude OR (95% CI) 1.00 1.14 (0.78–1.68) 1.82 (1.21–2.75)** 0.005
Adjusted OR (95% CI) 1.00 1.20 (0.77–1.89) 1.75 (1.05–2.92)* 0.03
Presence of PAD, n (%) 4 (1.6) 5 (2.0) 7 (2.8)
Crude OR (95% CI) 1.00 1.26 (0.33–4.73) 1.77 (0.51–6.13) 0.36
Adjusted OR (95% CI) 1.00 1.18 (0.31–4.57) 1.61 (0.42–6.16) 0.48
Women
Range, % > 105.7 94.1–105.7 < 94.1
Number of participants 258 258 259
Presence of arterial
stiffness, n (%)
120 (46.5) 150 (58.1) 153 (59.1)
Crude OR (95% CI) 1.00 1.60 (1.13–2.26)** 1.66 (1.17–2.35)** 0.004
Adjusted OR (95% CI) 1.00 1.50 (0.99–2.27) 1.28 (0.83–1.96) 0.25
Presence of PAD, n (%) 2 (0.8) 3 (1.2) 8 (3.1)
Crude OR (95% CI) 1.00 1.51 (0.25–9.09) 4.08 (0.86–19.40) 0.05
Adjusted OR (95% CI) 1.00 1.08 (0.17–7.12) 1.62 (0.27–9.67) 0.56
FEV1 forced expiratory volume in 1 s, PAD peripheral arterial disease
Adjusted for age, education, smoking, physical activity, waist circumference,
diastolic blood pressure, triglycerides, fasting plasma glucose, chronic
obstructive pulmonary disease, asthma and medications (aspirin and/or lipid
lowering medication)
Arterial stiffness: brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s
PAD: ankle-brachial index (ABI) < 0.9
P for sex interaction: (1) Arterial stiffness: 0.99; (2) PAD: 0.27
*:P < 0.05; **:P < 0.01
Appendix 2
Table 6 Adjusted odds ratios (ORs) for the presence of peripheral
vascular dysfunction by tertiles of FVC% predicted and by sex
FVC% predicted (%) P for
trend
Tertile 1 Tertile 2 Tertile 3
Men
Range, % > 100.6 87.3–100.6 < 87.3
Number of participants 251 251 251
Presence of arterial
stiffness, n (%)
168 (69.3) 181 (72.1) 208 (82.9)
Crude OR (95% CI) 1.00 1.28 (0.87–1.87) 2.39 (1.57–3.64)** < 0.001
Adjusted OR (95% CI) 1.00 1.35 (0.86–2.11) 2.18 (1.32–3.59)** 0.002
Presence of PAD,
n (%)
4 (1.6) 6 (2.4) 6 (2.4)
Crude OR (95% CI) 1.00 1.51 (0.42–5.43) 1.51 (0.42–5.43) 0.54
Adjusted OR (95% CI) 1.00 1.46 (0.39–5.44) 1.32 (0.35–5.04) 0.69
Women
Range, % > 105.7 94.1–105.7 < 94.1
Number of
participants
258 258 259
Presence of arterial
stiffness, n (%)
118 (45.7) 139 (53.9) 166 (64.1)
Crude OR (95% CI) 1.00 1.39 (0.98–1.96) 2.12 (1.49–3.01)** < 0.001
Adjusted OR (95% CI) 1.00 1.14 (0.76–1.72) 1.22 (0.79–1.89) 0.36
Presence of PAD, n (%) 3 (1.2) 3 (1.2) 7 (2.7)
Crude OR (95% CI) 1.00 1.00 (0.20–5.00) 2.36 (0.60–9.23) 0.18
Adjusted OR (95% CI) 1.00 0.70 (0.12–3.92) 1.18 (0.24–5.87) 0.82
FVC forced vital capacity, PAD peripheral arterial disease
Adjusted for age, education, smoking, physical activity, waist circumference,
diastolic blood pressure, triglycerides, fasting plasma glucose, chronic obstructive
pulmonary disease, asthma and medications (aspirin and/or lipid
lowering medication)
Arterial stiffness: brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s
PAD: ankle-brachial index (ABI) < 0.9
P for sex interaction: (1) Arterial stiffness: 0.19; (2) PAD: 0.69
**:P < 0.01
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Appendix 3
Table 7 Adjusted odds ratios (ORs) for the presence of peripheral
vascular dysfunction by tertiles of FEV1% predicted and by smoking
FEV1% predicted (%) P for
trend
Tertile 1 Tertile 2 Tertile 3
Non-smoker
Range, % > 104.1 91.4–104.1 < 91.4
Number of participants 344 344 345
Presence of arterial
stiffness, n (%)
181 (53.6) 211 (61.3) 230 (66.7)
Crude OR (95% CI) 1.00 1.43 (1.06–1.93)* 1.80 (1.32–2.45)** < 0.001
Adjusted OR (95% CI) 1.00 1.44 (1.00–2.07) 1.35 (0.93–1.98) 0.10
Presence of PAD,
n (%)
2 (0.6) 7 (2.0) 8 (2.3)
Crude OR (95% CI) 1.00 3.55 (0.73–17.22) 4.06 (0.86–19.26) 0.08
Adjusted OR (95% CI) 1.00 3.41 (0.69–16.86) 3.85 (0.78–18.97) 0.11
Ever-smoker
Range, % > 99.4 85.4–99.4 < 85.4
Number of
participants
165 165 165
Presence of arterial
stiffness, n (%)
112 (67.9) 112 (67.9) 134 (81.2)
Crude OR (95% CI) 1.00 1.00 (0.63–1.59) 2.05 (1.23–3.40)** 0.007
Adjusted OR (95% CI) 1.00 1.13 (0.65–1.96) 2.09 (1.09–4.01)* 0.03
Presence of PAD,
n (%)
2 (1.2) 4 (2.4) 6 (3.6)
Crude OR (95% CI) 1.00 2.02 (0.37–11.21) 3.08 (0.61–15.47) 0.16
Adjusted OR (95% CI) 1.00 2.56 (0.38–17.28) 1.47 (0.21–10.11) 0.81
FEV1 forced expiratory volume in 1 s, PAD peripheral arterial disease
Adjusted for age, sex, education, physical activity, waist circumference, diastolic
blood pressure, triglycerides, fasting plasma glucose, chronic obstructive
pulmonary disease, asthma and medications (aspirin and/or lipid
lowering medication)
Arterial stiffness: brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s
PAD: ankle-brachial index (ABI) < 0.9
P for smoking interaction: (1) Arterial stiffness: 0.50; (2) PAD: 0.69
*:P < 0.05; **:P < 0.01
Appendix 4
Table 8 Adjusted odds ratios (ORs) for the presence of peripheral
vascular dysfunction by tertiles of FVC% predicted and by smoking
FVC% predicted (%) P for
trend
Tertile 1 Tertile 2 Tertile 3
Non-smoker
Range, % > 102.6 90.8–102.6 < 90.8
Number of participants 344 344 345
Presence of arterial
stiffness, n (%)
176 (51.2) 204 (59.3) 242 (70.1)
Crude OR (95% CI) 1.00 1.39 (1.03–1.88)* 2.24 (1.64–3.07)** < 0.001
Adjusted OR (95% CI) 1.00 1.17 (0.82–1.68) 1.37 (0.94–2.01) 0.10
Presence of PAD,
n (%)
4 (1.2) 4 (1.2) 9 (2.6)
Crude OR (95% CI) 1.00 1.00 (0.25–4.03) 2.23 (0.77–6.49) 0.14
Adjusted OR (95% CI) 1.00 0.91 (0.22–3.78) 2.09 (0.61–7.24) 0.20
Ever-smoker
Range, % > 100.0 87.0–100.0 < 87.0
Number of participants 165 165 165
Presence of arterial
stiffness, n (%)
109 (66.1) 115 (69.7) 134 (81.2)
Crude OR (95% CI) 1.00 1.18 (0.74–1.88) 2.22 (1.34–3.68)* 0.002
Adjusted OR (95% CI) 1.00 1.07 (0.61–1.87) 1.98 (1.08–3.61)* 0.03
Presence of PAD,
n (%)
3 (1.8) 3 (1.8) 6 (3.6)
Crude OR (95% CI) 1.00 1.00 (0.20–5.03) 2.04 (0.50–8.29) 0.29
Adjusted OR (95% CI) 1.00 1.19 (0.22–6.54) 1.10 (0.23–5.05) 0.91
FVC forced vital capacity, PAD peripheral arterial disease
Adjusted for age, sex, education, physical activity, waist circumference, diastolic
blood pressure, triglycerides, fasting plasma glucose, chronic obstructive
pulmonary disease, asthma and medications (aspirin and/or lipid
lowering medication)
Arterial stiffness: brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s
PAD: ankle-brachial index (ABI) < 0.9
P for smoking interaction: (1) Arterial stiffness: 0.15; (2) PAD: 0.54
*:P < 0.05; **:P < 0.01
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